Videregen Therapeutics Report issue

For profit Phase 2
Founded: Liverpool United Kingdom (2011)

Organization Overview

First Clinical Trial
2020
NCT04435249
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Videregen Therapeutics

Active Ingredients

Drugs in Phase 2 Trials (1)

somatic mesenchymal stromal cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fistula (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1